Analyst Price Target is $30.50
▲ +152.07% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Janux Therapeutics in the last 3 months. The average price target is $30.50, with a high forecast of $35.00 and a low forecast of $26.00. The average price target represents a 152.07% upside from the last price of $12.10.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Janux Therapeutics.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.